Investigational drug for treating metastatic pancreatic cancer

Trial ID:
Darren Sigal, M.D.
This phase II study will test the safety and anti-tumor activity of an investigational anti-Leukemia Inhibitory Factor (Anti-LIF) drug called AZD0171, in combination with FDA approved standard of care Durvalumab and Chemotherapy for the treatment of locally advanced or metastatic pancreatic adenocarcinoma.

Inclusion Criteria

Patients must:
  • Have pathologically diagnosed locally advanced or metastatic pancreatic adenocarcinoma (mPDAC)
  • Be willing to submit an archived or fresh tumor specimen for central testing
  • Have normal organ function
  • Be over the age of 18 years old

Exclusion Criteria

Patients must not:
  • Have a history of another primary malignancy (non-melanoma skin cancers are eligible)
  • Have received systemic therapy for metastatic pancreatic adenocarcinoma.
  • Have previously received any immune-mediated therapy
  • Have central nervous system metastasis
  • Have a BRCA or sensitizing mutation for pancreatic adenocarcinoma
  • Have a history of thromboembolic events (blood clots)
  • Have a history of solid organ transplantation
  • Have a history of primary immunodeficiency
  • Have an ongoing or active infection or uncontrolled illness
  • Have an autoimmune disorder

Additional Info

  • This investigational drug is a first-in class-humanized monoclonal-antibody that binds with leukemia inhibitory factor. Anti-LIF's have the potential to aid standard-of-care chemotherapy to overcome resistance to chemotherapy and work alongside checkpoint inhibitors to achieve an antitumor response. Study participation will last until disease progression or unacceptable toxicity.
  • All treatments and physician visits during this study will take place at Scripps Clinic Torrey Pines (Geisel Pavilion)
  • Search NCT04999969 at website for more information.

Contact Info:

  • Clinical Research Services